Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZB131 (Ibentatug) in Advanced Solid Tumors
NCT05074472Phase 2Completed
- Sponsor
- ZielBio
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibentatug in solid tumor, pancreatic ductal adenocarcinoma (PDAC), ovarian serous adenocarcinoma, biliary tract cancer (BTC), ovarian serous cystadenocarcinoma, sponsored by ZielBio. Started Jan 2022; status: completed.
02
Drugs
ibentatug
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)ovarian serous adenocarcinomabiliary tract cancer (BTC)ovarian serous cystadenocarcinoma
Beyond the preview
Go deeper on NCT05074472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074472.